TRAVERE THERAPEUTICS

Legislation regarding clinical research for rare diseases and orphan drug development, and the Accelerated Approval pathway. Legislation to improve education and care pathways for patients with rare kidney disease.

Legislation regarding the Orphan Drug Tax Credit. Legislation to improve education and care pathways for patients with rare kidney disease.

Support for H.R.5539 - Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation impacting products approved under the Accelerated Approval pathway. Legislation regarding implementation of the Food and Drug Omnibus Reform Act of 2022. Legislation to improve education and care pathways for patients with rare kidney disease. H.R.6790, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients.

Support for H.R.5539 - Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding orphan drug pricing, value, and reimbursement, relative to the Inflation Reduction Act of 2022. Legislation regarding the Orphan Drug Exemption with the Inflation Reduction Act of 2022. H.R.2630/S.652, the SAFE Step Act; H.R.830/S.1375, the HELP Copays Act. Legislation to improve education and care pathways for patients with rare kidney disease. Policies regarding copay accumulators and impact on rare disease patients.

Support for H.R.5539 - Optimizing Research Progress Hope And New Cures Act (ORPHAN Cures Act). Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. Legislation regarding newborn screening. H.R.6790, New Era of Preventing End-Stage Kidney Disease Act. Policies regarding copay accumulators and impact on rare disease patients.